Even in mild cases, symptoms of COVID-19 can linger for at least 8 months, according to new research.
About 15% of health care workers who experienced mild COVID-19 reported at least one ongoing symptom at least 8 months after infection, according to a new study in Sweden.
The research letter, published in JAMA, detailed the ongoing COVID-19 Biomarker and Immunity study (COMMUNITY), including 323 seropositive and 1072 seronegative participants enrolled between April 15 and May 8 at Danderyd Hospital in Stockholm. Blood samples were evaluated every 4 months and participants responded to questionnaires.
“We see that a substantial portion of healthcare workers suffer from long-term symptoms after mild COVID-19,” corresponding author Charlotte Thalin, MD, PhD, of Danderyd Hospital and Karolinska Institute told Contagion. “The most commonly reported long-term symptoms were loss of smell and fatigue, symptoms which may seem trivial, but have a negative impact on work, social and home life in the long run. There are many reasons for controlling the spread of COVID-19, and this is one reason. Even if you are young and previously healthy, a mild COVID-19 infection may result in long-term consequences.”
About 26% of seropositive participants reported at least 1 moderate to severe symptom for at least 2 months, and 15% reported at least 1 moderate to severe symptoms for at least 8 months, compared with 9% and 3% of seronegative participants respectively.
About 8% of seropositive participants reported moderate to marked disruption of work life because of their symptoms, compared with 4% of seronegative participants. Moderate to marked disruptions to social life were reported among 15% of seropositive and 6% of seronegative participants, and disruptions to home life were reported among 12% and 5% respectively.
“Long-term symptoms are well-documented in severely ill and hospitalized COVID-19 patients,” Thalin said. “Data is however limited on the long-term effects of mild COVID-19 disease. I did not expect to see such a large portion of study participants reporting symptoms over as long as eight months after mild COVID-19.”
Most participants were considered low risk, with a median age of 43 among the seropositive group and 47 for the seronegative group with underlying chronic disease reported by 22% and 24% respectively.
About 11% of seropositive participants reported both disruption in any Sheehan Disability Scale category and at least 1 symptom lasting for at least 8 months.
“I think our data emphasizes the importance of adequate PPE and a wider implementation of RT-PCR screening in both healthcare workers and patients in healthcare settings to protect healthcare workers,” Thalin said. “Even mild COVID-19 infection can result in long-term symptoms hampering everyday life. However, it is noteworthy that we did not find an increased prevalence of other organ-specific long-term symptoms such as heart palpitations and neurological deficits such as concentration and memory impairment following mild COVID-19 in our study. Hopefully these type of long-term effects may affect primarily severely ill and hospitalized COVID-19 patients.”
Long-term effects of COVID-19 have been a topic of interest as the pandemic has progressed. One recent study showed that half of COVID-19 patients hospitalized in France reported symptoms, including fatigue, cognitive problems and dyspnea, 4 months after hospitalization. An earlier study in China found that more than three-quarters of hospitalized patients reported at least 1 symptom 6 months after infection. A small study from the University of Washington that included outpatients found that about a third of patients reported persistent symptoms an average of 6 months after the onset of COVID-19.
The COMMUNITY study is ongoing, with the next follow-up scheduled for May.
“The primary aim of the COMMUNITY study is to investigate long-term immunity after COVID-19 and vaccination, but we will also look into the prognosis of and possible underlying pathophysiological mechanisms behind COVID-19-related long-term symptoms, such as loss of taste and smell,” Thalin said.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.